INTEGRA LIFESCIENCES HOLDING (IART) Stock Fundamental Analysis
USA - NASDAQ:IART - US4579852082 - Common Stock
14.8 USD
-0.03 (-0.2%)
14.8 USD
0 (0%)
We assign a fundamental rating of 3 out of 10 to IART. IART was compared to 191 industry peers in the Health Care Equipment & Supplies industry. While IART is still in line with the averages on profitability rating, there are concerns on its financial health. IART is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
IART had positive earnings in the past year.
In the past year IART had a positive cash flow from operations.
IART had positive earnings in 4 of the past 5 years.
In the past 5 years IART always reported a positive cash flow from operatings.
1.2 Ratios
IART has a Return On Assets of -13.65%. This is comparable to the rest of the industry: IART outperforms 56.54% of its industry peers.
With a Return On Equity value of -48.20%, IART perfoms like the industry average, outperforming 51.31% of the companies in the same industry.
IART has a Return On Invested Capital of 4.68%. This is in the better half of the industry: IART outperforms 76.44% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for IART is below the industry average of 8.46%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.65% | ||
| ROE | -48.2% | ||
| ROIC | 4.68% |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
1.3 Margins
IART has a Operating Margin of 9.46%. This is in the better half of the industry: IART outperforms 76.96% of its industry peers.
In the last couple of years the Operating Margin of IART has declined.
IART has a Gross Margin of 57.24%. This is comparable to the rest of the industry: IART outperforms 54.97% of its industry peers.
IART's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.46% | ||
| PM (TTM) | N/A | ||
| GM | 57.24% |
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), IART is destroying value.
IART has less shares outstanding than it did 1 year ago.
IART has less shares outstanding than it did 5 years ago.
The debt/assets ratio for IART is higher compared to a year ago.
2.2 Solvency
IART has an Altman-Z score of 1.08. This is a bad value and indicates that IART is not financially healthy and even has some risk of bankruptcy.
IART's Altman-Z score of 1.08 is in line compared to the rest of the industry. IART outperforms 53.93% of its industry peers.
IART has a Debt/Equity ratio of 1.18. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of IART (1.18) is worse than 79.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.18 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.08 |
ROIC/WACC0.77
WACC6.1%
2.3 Liquidity
IART has a Current Ratio of 1.23. This is a normal value and indicates that IART is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.23, IART is doing worse than 80.10% of the companies in the same industry.
A Quick Ratio of 0.73 indicates that IART may have some problems paying its short term obligations.
The Quick ratio of IART (0.73) is worse than 87.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.23 | ||
| Quick Ratio | 0.73 |
3. Growth
3.1 Past
IART shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -20.85%.
IART shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.35% yearly.
The Revenue has been growing slightly by 3.53% in the past year.
IART shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.20% yearly.
EPS 1Y (TTM)-20.85%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%-28.57%
Revenue 1Y (TTM)3.53%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%-0.61%
3.2 Future
Based on estimates for the next years, IART will show a small growth in Earnings Per Share. The EPS will grow by 2.21% on average per year.
Based on estimates for the next years, IART will show a small growth in Revenue. The Revenue will grow by 3.88% on average per year.
EPS Next Y-11.84%
EPS Next 2Y-1.87%
EPS Next 3Y2.21%
EPS Next 5YN/A
Revenue Next Year3.53%
Revenue Next 2Y3.93%
Revenue Next 3Y3.88%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 6.61, which indicates a rather cheap valuation of IART.
Compared to the rest of the industry, the Price/Earnings ratio of IART indicates a rather cheap valuation: IART is cheaper than 96.34% of the companies listed in the same industry.
IART is valuated cheaply when we compare the Price/Earnings ratio to 27.20, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 6.00, the valuation of IART can be described as very cheap.
Based on the Price/Forward Earnings ratio, IART is valued cheaper than 98.95% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.70. IART is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.61 | ||
| Fwd PE | 6 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IART is valued cheaply inside the industry as 92.67% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 8.96 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.87%
EPS Next 3Y2.21%
5. Dividend
5.1 Amount
No dividends for IART!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
14.8
-0.03 (-0.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners100.14%
Inst Owner Change0.03%
Ins Owners3.31%
Ins Owner Change1.39%
Market Cap1.15B
Analysts54.44
Price Target16.76 (13.24%)
Short Float %10.74%
Short Ratio5.65
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.27%
Min EPS beat(2)-6.76%
Max EPS beat(2)2.22%
EPS beat(4)3
Avg EPS beat(4)2.45%
Min EPS beat(4)-6.76%
Max EPS beat(4)11.12%
EPS beat(8)3
Avg EPS beat(8)-0.11%
EPS beat(12)6
Avg EPS beat(12)3.26%
EPS beat(16)8
Avg EPS beat(16)3.79%
Revenue beat(2)1
Avg Revenue beat(2)0.78%
Min Revenue beat(2)-1.58%
Max Revenue beat(2)3.14%
Revenue beat(4)1
Avg Revenue beat(4)-0.4%
Min Revenue beat(4)-2.51%
Max Revenue beat(4)3.14%
Revenue beat(8)1
Avg Revenue beat(8)-0.95%
Revenue beat(12)2
Avg Revenue beat(12)-0.82%
Revenue beat(16)3
Avg Revenue beat(16)-0.75%
PT rev (1m)0%
PT rev (3m)-1.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-24.66%
EPS NY rev (1m)-1.2%
EPS NY rev (3m)-1.16%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.09%
Revenue NY rev (1m)0.18%
Revenue NY rev (3m)0.18%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.61 | ||
| Fwd PE | 6 | ||
| P/S | 0.71 | ||
| P/FCF | N/A | ||
| P/OCF | 16.27 | ||
| P/B | 1.11 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.96 |
EPS(TTM)2.24
EY15.14%
EPS(NY)2.47
Fwd EY16.66%
FCF(TTM)-0.61
FCFYN/A
OCF(TTM)0.91
OCFY6.15%
SpS20.82
BVpS13.33
TBVpS-9.83
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.65% | ||
| ROE | -48.2% | ||
| ROCE | 5.61% | ||
| ROIC | 4.68% | ||
| ROICexc | 5.16% | ||
| ROICexgc | 18.86% | ||
| OM | 9.46% | ||
| PM (TTM) | N/A | ||
| GM | 57.24% | ||
| FCFM | N/A |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
ROICexc(3y)6.8%
ROICexc(5y)7%
ROICexgc(3y)25.35%
ROICexgc(5y)25.69%
ROCE(3y)7.3%
ROCE(5y)7.36%
ROICexcg growth 3Y-1.99%
ROICexcg growth 5Y0.59%
ROICexc growth 3Y-12.19%
ROICexc growth 5Y-7.26%
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
F-Score5
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.18 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 4.06 | ||
| Cap/Depr | 79.68% | ||
| Cap/Sales | 7.29% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 23.48% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.23 | ||
| Quick Ratio | 0.73 | ||
| Altman-Z | 1.08 |
F-Score5
WACC6.1%
ROIC/WACC0.77
Cap/Depr(3y)58.38%
Cap/Depr(5y)54.07%
Cap/Sales(3y)4.82%
Cap/Sales(5y)4.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.85%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%-28.57%
EPS Next Y-11.84%
EPS Next 2Y-1.87%
EPS Next 3Y2.21%
EPS Next 5YN/A
Revenue 1Y (TTM)3.53%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%-0.61%
Revenue Next Year3.53%
Revenue Next 2Y3.93%
Revenue Next 3Y3.88%
Revenue Next 5YN/A
EBIT growth 1Y-36.46%
EBIT growth 3Y-13.07%
EBIT growth 5Y-6.81%
EBIT Next Year17.58%
EBIT Next 3Y10.16%
EBIT Next 5YN/A
FCF growth 1Y-130.53%
FCF growth 3Y-61.56%
FCF growth 5Y-31.13%
OCF growth 1Y-65.94%
OCF growth 3Y-25.46%
OCF growth 5Y-10.98%